Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.73 - $1.38 $144 - $273
198 Added 180.0%
308 $0
Q1 2024

Nov 05, 2024

SELL
$1.02 - $1.3 $201 - $257
-198 Reduced 64.29%
110 $0
Q1 2024

May 15, 2024

SELL
$1.02 - $1.3 $103 - $131
-101 Reduced 47.87%
110 $0
Q4 2023

Feb 14, 2024

SELL
$0.75 - $1.49 $4,727 - $9,391
-6,303 Reduced 96.76%
211 $0
Q3 2023

Nov 14, 2023

BUY
$1.23 - $2.25 $8,012 - $14,656
6,514 New
6,514 $8,000
Q1 2023

May 15, 2023

SELL
$1.34 - $2.62 $4,623 - $9,039
-3,450 Reduced 59.99%
2,301 $3,000
Q4 2022

Feb 14, 2023

SELL
$1.44 - $3.44 $7,236 - $17,286
-5,025 Reduced 46.63%
5,751 $9,000
Q3 2022

Nov 14, 2022

BUY
$3.35 - $5.55 $891 - $1,476
266 Added 2.53%
10,776 $36,000
Q2 2022

Aug 15, 2022

SELL
$3.12 - $7.52 $6,726 - $16,213
-2,156 Reduced 17.02%
10,510 $38,000
Q1 2022

May 16, 2022

SELL
$6.26 - $14.42 $31,969 - $73,642
-5,107 Reduced 28.73%
12,666 $91,000
Q4 2021

Feb 14, 2022

BUY
$11.35 - $21.18 $138,878 - $259,158
12,236 Added 220.99%
17,773 $242,000
Q3 2021

Nov 15, 2021

BUY
$18.17 - $24.7 $34,141 - $46,411
1,879 Added 51.37%
5,537 $116,000
Q2 2021

Aug 16, 2021

BUY
$20.08 - $29.02 $73,452 - $106,155
3,658 New
3,658 $88,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.9M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.